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Mammalian peroxiredoxin V (PrdxV) is a multifunctional protein that protects cells from DNA damage
and inhibits stress-induced apoptosis. However, PrdxV is also known to be involved in modulating
lipopolysaccharide (LPS)-induced host cell signaling, but its precise role is not fully understood. In this
study, we used stably transfected RAW264.7 cells and transiently transfected 293-mTLR4-MD2-CD14
cells expressing wild-type (WT) or mutant (C48S) PrdxV to characterize the function and mechanism of
action of PrdxV in LPS-induced immune responses. We found that PrdxV selectively reduces production
of interleukin 6 (IL-6) by inhibiting activation of signal transducer and activator of transcription 5 (Stat5)
through interaction with Jak2. Notably, this activity of PrdxV was dependent on its catalytic Cys48
residue, but not its peroxidase activity. The binding of to Jak2 effectively inhibited Jak2 phosphorylation,
but PrdxV did not act as efﬁciently as SOCS1 (suppressor of cytokine signaling 1). Our results suggest that
PrdxV is a key mediator contributing to the regulation of LPS/TLR4-induced immune responses.
& 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-SA license. Introduction
Lipopolysaccaride (LPS) is an outer membrane component of
gram-negative bacteria and a potent activator of monocytes and
macrophages. Macrophages recognize LPS via the Toll-like recep-
tor 4 (TLR4) complex, which is composed of TLR4, myeloid
differentiation protein-2 (MD-2), and CD14 [1], and inducesr Inc.
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Open access under CC BY-expression of a variety of proinﬂammatory cytokines, including
tumor necrosis factor α (TNF-α), interleukin (IL)-1β, IL-6, IL-12,
IL-8, and the interferons (IFNs) [2].
LPS-induced TLR4 activation is mediated by the adaptor mole-
cules myeloid differentiation primary-response gene 88 (MyD88),
MyD88-adaptor-like protein (MAL), TIR (Toll/I-1 receptor) domain-
containing adaptor inducing interferon-β (TRIF), and TRIF-related
adaptor molecule (TRAM) [1]. The signal transduced by each adaptor
activates downstream signaling molecules that include nuclear
factor-κB (NF-κB), mitogen-activated protein kinases (MAPKs), and
TRIF-IFN-regulatory factor (IRF3) [3,4]. In addition, the Jak2–Stat5
pathway is also reportedly activated by LPS/TLR4, though the adaptor
molecule for Jak2 has not yet been identiﬁed [5]. Activation of these
signaling cascades leads to the abundant secretion of the proinﬂam-
matory cytokines TNF-α, IL-6, IFN-β, and RANTES [5–8].
PrdxV, an atypical 2-Cys peroxiredoxin, is a thiol-dependent
peroxidase that reduces hydrogen peroxide (H2O2), alkyl hydroper-
oxides, and peroxynitrite [9,10], and exhibits different biochemical and
structural features than typical 2-Cys Prdxs [11]. Functionally, PrdxV
reacts with a more modest rate constant toward H2O2 (105 M1 s1)
than toward peroxynitrite (107 M1 s1) or alkyl hydroperoxide
(106 M1 s1) [9,10]. By contrast, erythrocyte PrdxII, a typical 2-Cys
Prdx, reacts with a rate constant of 108 M1 s1 toward H2O2 andNC-SA license. 
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to hyperoxidation by H2O2 [13]. Because the reversible inactivation of
Prdxs by hyperoxidation is one of the mechanisms regulated by H2O2-
mediated signaling [14,15], PrdxV would appear to be inadequate as a
redox sensor. Moreover, PrdxV exhibits broad subcellular localization,
being present in mitochondria, peroxisomes, the nucleus, and the
cytosol [16–18]. These characteristics may explain why PrdxV is
involved in speciﬁc functions and mechanisms that do not involve
other Prdxs that are more reactive with H2O2.
From the time of its discovery, PrdxV has consistently been
reported to be involved in inﬂammation. For example, levels of PrdxV
mRNA are reportedly increased in the lungs of rats during acute
inﬂammation induced by LPS [19]. Similarly, bacterial inﬂammation in
mice leads to increases in pulmonary PrdxV [20]. PrdxV is also
increased during virus-induced inﬂammation, and appears to exert a
protective effect against oxidative stress in pulmonary epithelial cells
[21]. One recent study has shown that PrdxV is up-regulated in
LPS-stimulated primary macrophages via a TRIF-dependent, MyD88-
independent signaling pathway [22]. In addition, up-regulation of
PrdxV signiﬁcantly inhibits LPS-stimulated macrophage cells through
blockade of the MAPKs p38 and JNK [22]. Most recently, microglial
PrdxV was shown to be induced to modulate the balance between
proinﬂammatory and anti-inﬂammatory signals [23]. However, the
regulation of inﬂammatory cytokines in response to LPS-mediated
induction of PrdxV has not been well studied.
In the present study, we observed that cytosolic PrdxV was
selectively induced in LPS-stimulated macrophages. Interestingly,
production of IL-6, but not other cytokines (TNF-α, IFN-β, and RANTES),
was reduced in Raw264.7 cells overexpressing PrdxV (PrdxVWT). In
addition, LPS-induced phosphorylation of Jak2, and subsequently
Stat5, was signiﬁcantly impaired in PrdxVWT cells, and the observed
effects were blocked by mutation of the catalytic Cys48 residue
in PrdxV. Likewise, the binding of PrdxV to Jak2 was also Cys48-
dependent. Our ﬁndings suggest that PrdxV contributes to the
regulation of LPS-induced IL-6 production via a PrdxV–Jak2 pathway
that is independent of PrdxV′s peroxidase activity.Materials and methods
Cell culture
Thioglycollate-induced peritoneal macrophages from C57BL/6J
mice and mouse Raw264.7 cells (ATCC, TIB-71) were cultured in
complete medium (DMEM supplemented with 10% fetal bovine
serum, 50 U/ml penicillin, and 50 μg/ml streptomycin) at 37 1C under
a humidiﬁed 5% CO2 atmosphere. Stably transfected RAW264.7 cells
ectopically expressing the indicated constructs (PrdxVMock, PrdxVWT,
and/or PrdxVC48S) were maintained in complete medium containing
500 mg/ml of G418. 293-mTLR4-MD2-CD14 cells (InvivoGen, San
Diego, USA) were maintained in growth medium (DMEM supplemen-
ted with 10% FBS, 50 U/ml penicillin, 50 μg/ml streptomycin, 100 μg/ml
normocin) containing selective antibiotics (10 μg/ml blasticidin and
50 μg/ml HygroGold). The protocols for collection of peritoneal macro-
phages from mice were reviewed and approved by the Animal Care
Regulations (ACR) Committee of Chonnam National University (Acces-
sion Number: CNU IACUC-YB-2008-1).
Reagents and antibodies
Escherichia coli (0111:B4) LPS, N-acetyl-L-cysteine (NAC), and anti-
HA agarose conjugate clone HA-7 were purchased from Sigma-
Aldrich. Agarose-conjugated anti-GFP was from MBL. 5-(and-6)-
chloromethyl-2′,7′-dichlorodihydroﬂuorescein diacetate, acetyl
ester (CM-H2DCFDA) was from Molecular Probes (Invitrogen, CA,
USA). Antibodies against Jak2, Stat5, phospho-Jak2, phospho-Stat5,phospho-ERK, phospho-JNK, phospho-c-Jun, phospho-p38, Flag,
c-Myc, HA, phosphor-NF-κB p65, and IκBα were all from Cell
Signaling Technology (Danvers, MA, USA). Speciﬁc antibodies
against PrdxI-VI were obtained from the Lab Frontier Life Science
Institute (Seoul, Korea). An antibody against SOCS1 was purchased
from Abnova Corporation (Taipei, Taiwan), and an antibody against
EGFP was from Abcam Corporation.
Plasmid construction
For stable expression of PrdxV in mouse Raw264.7 cells, mouse
PrdxV cDNA without the signal sequence was ampliﬁed by PCR using
primers containing the MluI and XhoI restriction sites. The ampliﬁed
PCR products were inserted into the pCR3.1 vector, which was
modiﬁed by insertion of a matrix attachment region (MAR) to induce
stable expression, and by substitution of the chicken β-actin/rabbit
β-globin hybrid promoter (AG) by the cytomegalovirus immediate
early promoter (CMV-IE) from pCAGGS. Substitution of Cys48 in the
active site of PrdxV with Ser (C48S) was accomplished through
standard PCR-mediated site-directed mutagenesis, after which the
mutant was subcloned into the same expression vector used for wild-
type (WT) PrdxV. For transient expression in 293-mTLR4-MD2-CD14
cells, mouse WT PrdxV cDNA or a cysteine mutant (C48S, C73S, C152S,
or C48/152S) was ampliﬁed by PCR using primers containing EcoRI and
BglII sites frommouse PrdxV/pCR3.1 constructs as a template. The PCR
products were then inserted into pCMV-HA vector (Clontech Labora-
tories, CA, USA). Mouse Jak2 was ampliﬁed by PCR using mouse Jak2/
pEF-BOS plasmid [24], which was a gift from Dr. Kwang-Hyun Baek
(Pochon CHA University, Korea), as a template. The PCR products were
cloned into the ScaI and SalI sites in pEGFP-C3 vector (Clontech). Myc-
tagged mouse Stat5b [25] and Flag-tagged Socs1 [26] were gifts from
Dr. Jane Visvader (The Walter and Eliza Hall Institute of Medical
Research, Australia) and Dr. Dong-Soo Im (KRIBB, Korea), respectively.
Plasmid DNA constructs were transfected into mouse RAW264.7 cells
and 293-mTLR4-MD2-CD14 cells using Lipofectamine 2000 reagent
(Invitrogen, Carlsbad, CA, USA) for stable expression and transient
expression, respectively.
Preparation of stable cell lines
To establish Raw 264.7 cell lines overexpressing PrdxV, the cells
were seeded into six-well plates at 0.5106 cells per well. They were
then transfected with 2 μg of PrdxVMock, PrdxVWT, or PrdxVC48S DNA
using 6 μl of Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA,
USA) in antibiotic-free DMEM. Beginning 1 day after transfection,
transfectants were selected in DMEM containing 500 μg/ml G418,
which was refreshed every 2 days for 2 weeks. Colonies surviving in
the selection medium were collected and plated in 24-well plates.
Cells stably overexpressing PrdxV were identiﬁed by immunoblotting
with anti-PrdxV and anti-β-actin antibodies or by genomic PCR
analysis using primers 5′-GAAGAACTCGTCAAGAAGGC-3′ (forward)
and 5′-GATGGATTGCACGCAGGTTC-3′ (reverse), which contain a
neomycin-speciﬁc sequence. β-Actin served as a loading control.
Cell fractionation
To determine the levels of mitochondrial and cytosolic PrdxV
induced by LPS stimulation, 0.5106 RAW264.7 cells were treated
with 1 mg/ml LPS for 3 h. The cells were then washed with prechilled
PBS and lysed in cytosolic lysis buffer (10mM Tris-HCl [pH 7.5], 0.3 M
sucrose, 10 μM aprotinin A, 10 μM pepstatin, 10 μM leupeptin, 1 mM
PMSF). The resultant cell lysates were homogenized on ice using
homogenizer, after which the homogenates were spun at 10,000g for
60 min at 4 1C. The resultant supernatant was used as the cytosolic
fraction, and insoluble pellet, including themitochondria, was dissolved
in mitochondria lysis buffer (10mM Tris-HCl, pH 7.5, 1% Triton X-100,
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1 mM PMSF). The lysate was then spun at 10,000 g for 30 min at 4 1C,
and the supernatant was used as a mitochondrial fraction.
Enzyme-linked immunosorbent assay
RAW264.7 cells were seeded into 6-well plates at 0.5106 or
1106 cells per well. After 1 day, the cells were treated with
complete medium containing 1 μg/ml LPS, as indicated in the
ﬁgures. Samples of culture medium were then collected for ELISA
analysis. The collected samples were centrifuged at 13,200 rpm for
10 min, after which the supernatants were assayed for IL-6 and
TNF-α using using two commercial products: a Quantikine immu-
noassay kit (R&D Systems, Minneapolis, MN, USA) and an ELISA
MAX Deluxe SET kit (BioLegend, San Diego, CA, USA). The levels of
IFN-β and RANTES were assayed using a Quantikine immunoassay
kit (R&D Systems, Minneapolis, MN, USA).
Real-time PCR
For real-time PCR, total RNA was extracted from cells using QIAzol
lysis reagent (Qiagen Science, Maryland, USA), after which cDNA was
reverse transcribed from 1-μg samples of total RNA using Prime Script
RT reagent (TaKaRa, Shiga, Japan) with oligo-dT and random hexamer.
Real-time PCR (50 1C, 2 min; 95 1C, 10 min; 50 cycles of 95 1C, 15 s and
60 1C, 1 min) was performed using SYBR Premix EX Taq (TaKaRa,
Shiga, Japan) and an ABI Prism 7300 Real-Time PCR system (Applied
Biosystems, Foster City, CA, USA). The primer sequences used for real-
time PCR were as follows: for GAPDH, 5′-TGTGTCCTCGTGGATCTGA-3′
(F) and 5′-GATGCCTGCTTCACCACCTT-3′ (R); for IL-6, 5′-CTC GGCA-
AACCTAGTGAGTTA-3′ (F) and 5′ -ACACACGGATATATTTTCTGACCA-
CAGT-3′ (R); for TNF-α, 5′ -TCTGTCTCAGAATGAGGCTGGAT-3′ (F) and
5′-GCATTGCACC TCAGGGAAGA-3′ (R); for IFN-β, 5′-GAGCTATTACTG-
GAGGGTGCAAA-3′ (F) and 5′-ATCTCTGCTCGGACCACCAT-3′ (R); for
RANTES, 5′-AGCTAGGATAGAGGGTTTCT TGATTCT-3′ (F) and 5′-
CCCCAAGCTGGCTAGGACTA-3′ (R); for G-CSF, 5′-GGTGTC CTGGCCATT
TCGTA-3′ (F) and 5′-AAGGGCTTTCTGCTCAGGTCTA-3′ (R); and for0
PrdxV








Fig. 1. Up-regulation of PrdxV in LPS-stimulated macrophages. (A, B) RAW264.7 cells and
cells were then harvested at the indicated times, and levels of Prdxs were determined by
Prdxs/β-actin protein expression, as obtained using densitometry (bottom of A). (C) To
were treated with 1 mg/ml LPS, after which the cells were fractionated as described unde
with anti-PrdxIII (as a mitochondrial marker) and anti-GAPDH (as a cytosolic marker).PrdxV, 5′TTATTGGATGATTCTTTGGTGTCTCT-3′ (F) and 5′-CCTTCAC-
TATGCCGT TGTCTATCAC-3′ (R).
Measurement of intracellular ROS
Levels of intracellular reactive oxygen species (ROS) were assessed
using 5,6-chloromethyl-2′,7′-dichlorodihydroﬂuorescein diacetate
(Invitrogen). RAW264.7 (1.0106) cells were incubated with 1 mg/
ml LPS in phenol red-free complete medium for 12 h at 37 1C under a
humidiﬁed 5% CO2 atmosphere, after which they were washed with
Hank′s buffered salt solution (HBSS). The cells were then harvested
using Cell Dissociation Solution (Sigma-Aldrich, Louis, MO, USA),
washed once with HBSS, and incubated with 4 μM CM-H2DCFH-DA
(Invitrogen, Carlsbad, CA, USA) for 20 min at 37 1C. Thereafter, the
cells were washed with serum-free, phenol red-free medium and
suspended with phenol red-free medium. Finally, the cells were
analyzed using ﬂow cytometry to quantify the ﬂuorescent oxidized
DCFH (Cytomics FC500, Beckman Coulter, Fullerton, CA, USA).
Immunoprecipitation assay
One day prior to transfection, 293-mTLR4-MD2-CD14 cells were
seeded into 60-mm dishes at 1106 cells per dish. The cells were
then cotransfected with mammalian expression constructs encoding
tagged (GFP, Myc and HA, respectively) mouse Jak2 (0.5 μg), Stat5b
(0.8 μg), and PrdxV (WT or C48S, C73S, C152S, or C48/152S; 1 μg).
Twenty-four hours after transfection, the cells were incubated for 3 h
in the absence or presence of 0.1 μg/ml of LPS and then lysed in 500 μl
of cold lysis buffer (20 mM Tris-HCl, pH 7.5, 100 mMNaCl, 1 mM EDTA,
0.5% Triton X-100, 1 mM NaF, 1 mM Na3VO4, 0.1 mM AEBSF, 1 μg/ml
pepstatin, 1 μg/ml aprotinin, 0.5 μg/ml leupeptin, 1 mM PMSF). After
centrifugation, samples of the supernatants (250 μg) were separately
immunoprecipitated using GFP-agarose beads (prewashed 10 μl of a
50% slurry) or HA-agarose beads (prewashed 10 μl of a 50% slurry) for
12 h at 4 1C. The beads were then washed three times with cold PBS,
and the bound protein was recovered by boiling in SDS-PAGE sample
buffer. Thereafter, the proteins were immunoprecipitated with GFP- or)











peritoneal macrophages isolated from mice were stimulated with 1 mg/ml LPS. The
immunoblotting with anti-Prdx antibodies (I–VI). The bar graph shows the means of
investigate the cellular localization of PrdxV after LPS stimulation, RAW264.7 cells
r Materials and methods. Fractionation samples were analyzed by immunoblotting
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immunoblotted with anti-GFP, anti-Myc, and anti-HA antibodies. In a
separate protocol, the expression level of each protein used for
immunoprecipitation was also determined using the same antibodies.Western blotting
To detect phosphorylated proteins, cell lysates were prepared in
RIPA buffer containing phosphatase and protease inhibitors (50 mM
Tris-HCl, pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.5% sodium deoxycho-
late, 0.1% SDS, 1 mM NaF, 1 mM Na3VO4, 0.1 mM AEBSF, 1 μg/ml
pepstatin, 1 μg/ml aprotinin, 0.5 μg/ml leupeptin, 1 mM PMSF). Protein
concentrations were determined using BCA protein assays (Pierce,
Rockford, IL), after which aliquots of cell extract containing 30 mg or





















































Fig. 2. IL-6 production is selectively inhibited by PrdxV overexpression. (A) RAW264.7
Stable overexpression of PrdxV was selected by immunoblotting with anti-PrdxV and β-a
(2), were stimulated with 1 mg/ml LPS for the indicated times (0, 3, 6, and 12 h), after w
Cytokine protein levels were measured using ELISAs (B), while cytokine mRNA levels we
three experiments. *P>0.1; **Po0.05; and ***Po0.005.Statistical analysis
The data were derived from three independent experiments
and expressed as means 7 SEM. Standard t tests were used to
assess the signiﬁcance of differences between and among groups.
All statistical analyses were performed using SigmaPlot 9.0 soft-
ware. P values less than 0.05 were considered signiﬁcant.Results
Cytosolic PrdxV is up-regulated in macrophages stimulated with LPS
To assess the involvement of Prdxs in the immune response of
macrophages to LPS, we ﬁrst used Western blotting to examine the














































LPS incubation time (h)
cells were stably transfected with empty vector (Mock) or wild-type PrdxV (WT).
ctin (loading control). (B, C) Two selected PrdxVWT clones, PrdxVWT(1) and PrdxVWT
hich the culture media and cells were harvested and analyzed for IL-6 and TNFα.
re measured using real-time PCR (C). The data are presented as the means 7 SD of
H.-I. Choi et al. / Free Radical Biology and Medicine 65 (2013) 270–279274LPS. On LPS stimulation, PrdxV expression time dependently increased
in the RAW264.7 mouse macrophage line (Fig. 1A) and in mouse
peritoneal macrophages (Fig. 1B), whereas the expression of other
Prdxs was unchanged. Because PrdxV is broadly distributed within
cells [11], we next determined the subcellular localization of the up-
regulated PrdxV by lysing LPS-treated Raw264.7 cells and separating
the lysates into soluble and insoluble fractions. PrdxIII, a Prdx isotype
mainly found in mitochondria, was used as a marker of the insoluble
fraction. We found that PrdxV was signiﬁcantly increased only in the
soluble fraction after LPS treatment (Fig. 1C). These results suggest that
it is cytosolic PrdxV that is involved in LPS-induced inﬂammation.
PrdxV regulates LPS-induced IL-6 production
To examine the effects of the up-regulated PrdxV in LPS-treated
macrophages, we stably transfected RAW264.7 cells with empty
vector (PrdxVMock) or a vector encoding mouse WT PrdxV (PrdxVWT)
(Fig. 2). The transfectants were screened using Western blotting to
assess PrdxV levels (Fig. 2A) or by genomic insertion using genomic
PCR (data not shown). Among the stable cell lines, two PrdxVWT
clones, PrdxVWT(1) and PrdxVWT(2), were compared to PrdxVMock cells.
The levels of other Prdx isotypes, catalase, and GpxI were unaffected in
these cells (Supplementary Fig. S1).
After stimulating the cells with LPS, we ﬁrst analyzed the
protein and mRNA levels of proinﬂammatory cytokines (Fig. 2B
and C and Supplementary Fig. S2). In PrdxVMock cells, LPS induced
signiﬁcant time-dependent production of TNF-α, IL-6, RANTES, and



























Fig. 3. Role of intracellular ROS in LPS-induced proinﬂammatory cytokine expression. (
RAW264.7 cells were incubated for 12 h with 1 mg/ml LPS in the presence or absence of
real-time PCR. The levels of PrdxV protein (lower panel) were determined by immunoblo
or absence of 20 mM NAC, the culture media were collected and IL-6 and TNF-α levelsprotein were diminished in PrdxVWT cells, although there were no
noticeable changes in the production of the other cytokines tested
(TNF-α, IFN-β, and RANTES). This suggests that PrdxV is speciﬁcally
associated with LPS-induced IL-6 regulation in macrophages.
PrdxV modulates LPS-induced IL-6 production in a catalytic cysteine
(Cys48)-dependent manner
ROS are known to act as proinﬂammatory mediators in LPS-
stimulated macrophages. Typically, 2-Cys Prdxs have a high afﬁnity
for H2O2, enabling them to eliminate the intracellular H2O2 generated
in response to TNF-α stimulation [27], so that PrdxII-deﬁcient macro-
phages showed an enhanced inﬂammatory response mediated by
up-regulation of H2O2 [28]. In addition, recent studies have noted that
PrdxV induction is associated with an increase in ROS/NO levels in
LPS-stimulated microglial cells, where it appears to act as an anti-
inﬂammatory antioxidant [23]. For those reasons, we compared the
effects of PrdxV with those of the antioxidant NAC, a glutathione
precursor, to determine whether PrdxV′s inhibition of LPS-induced
IL-6 production is secondary to an effect on intracellular ROS.
Consistent with an earlier report [23], levels of PrdxV mRNA and
protein correlated with the ROS level by NAC treatment (Fig. 3A and
Supplementary Fig. S3A). Furthermore, the reduction in ROS levels
elicited by NAC led to reductions in the proinﬂammatory cytokines
IL-6 and TNF-α (Fig. 3B). We further compared the antioxidant effect of
PrdxII and catalase, a known peroxidase enzyme, in LPS-induced
proinﬂammatory cytokine production. Although anti-inﬂammatory




























A) To assess the role of ROS in LPS-induced proinﬂammatory cytokine expression,
20 mM NAC. The relative levels of PrdxV mRNA (upper panel) were assayed using
tting with speciﬁc antibodies. (B) After incubation for 12 h with LPS in the presence
were determined using ELISAs.
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reduction of IL-6 and TNF-α production by LPS stimulation, like as anti-
inﬂammatory effect of NAC (Supplementary Fig. S3C–E). In contrast to
the effect of NAC, however, overexpression of PrdxV selectively down-
regulated IL-6 production; it had no effect on other cytokines (Fig. 2).
To then determine whether PrdxV peroxidase activity is
required for the enzyme′s negative regulation of IL-6, we estab-
lished Raw264.7 cells stably expressing a PrdxV mutant in which
the catalytic Cys48 was substituted with Ser (PrdxVC48S cells)
(Fig. 4A). In PrdxVWT cells, overexpression of WT PrdxV had no
effect on TNF-α levels, whereas IL-6 levels were notably reduced.
In PrdxVC48S cells, by contrast, overexpression of the catalytically
inactive mutant PrdxV had no effect on IL-6 levels (PrdxVWT vs
PrdxVC48S: Po0.005 by 6 h treatment, Po0.05 at 12 h) (Fig. 4C).
More interestingly, we found no meaningful difference between
the LPS-induced ROS levels in PrdxVMock vs PrdxVWT cells
(P¼0.48) or PrdxVWT vs PrdxVC48S cells (P>0.1) (Fig. 4B). Taken
together, these results imply that the up-regulation of PrdxV
negatively regulates IL-6, not ROS, and that the effect on IL-6 is
dependent on the catalytic Cys48 residue of PrdxV.
PrdxV modulates LPS-induced Jak2–Stat5 activation
Activation of the NF-κB and MAPK pathways plays an essential role
in mediating the response to proinﬂammatory stimuli [29]. Therefore,
to investigate the involvement of these signals in IL-6 regulation byMock




























Fig. 4. PrdxV catalytic Cys48-dependent inhibition of IL-6. (A) To assess the involvement
empty vector (Mock), WT PrdxV, or mutant (C48S) PrdxV were analyzed using speciﬁc an
and Raw264.7C48S cells were stimulated with 1 μg/ml LPS for 12 h, after which DCF ﬂuor
as fold increases normalized to the no-treatment cells. (C) Levels of IL-6 (left panel) an
times (0, 3, 6, and 12 h). The data are presented as means 7 SD of three experiments.PrdxV, we compared the phosphorylation levels of various signaling
molecules in PrdxVMock and PrdxVWT cells during LPS stimulation
(Fig. 5). The levels of phospho-ERK1/2, -JNK, -c-Jun, and -p38 MAPK
were little affected in PrdxVWT cells, as compared to PrdxVMock cells,
suggesting that overexpression of PrdxV was not directly involved in
the activation of MAPK signaling (Fig. 5A). In addition, activation of the
NF-κB was assessed based on IκB degradation, the level of phosphory-
lated NF-κB p65 (Fig. 5A), and the level of IκBζ induction (Fig. 5B).
Because IL-6 is reportedly required for induction of IκBζ following LPS
stimulation [30], we used real-time PCR to examine the expression
level of granulocyte-colony stimulating factor (G-CSF), which is
regulated by IκBζ (Fig. 5B). We found that expression of G-CSF mRNA
differed little between PrdxVWT and PrdxVMock cells. These results
suggest that IL-6 regulation by PrdxV involves a signaling pathway
other than the NF-κB and MAPK pathways.
In a recent study, LPS was shown to activate the Jak2–Stat5
signaling pathway, which is involved in IL-6 production through
sequential phosphorylation of Jak2 and Stat5. [5]. We therefore
investigated the activation of Jak2 and Stat5 using speciﬁc anti-
bodies against phospho-Jak2 and phospho-Stat5 (Fig. 5C). In the
absence of LPS stimulation, a low basal level of Jak2 phosphoryla-
tion (activation) was detected in PrdxVMock cells. The evoked
phosphorylation of Jak2 and Stat5 peaked after 3 h of LPS stimula-
tion. Interestingly, however, LPS-induced phosphorylation of Jak2
and Stat5 was signiﬁcantly reduced by overexpression of PrdxVWT.

















































of PrdxV catalytic activity on IL-6 regulation, RAW264.7 cells stably transfected with
ti-PrdxV. (B) To assess ROS levels, CM-H2DCFDA-loaded Raw264.7Mock, Raw264.7WT,
escence was measured by ﬂow cytometry. Relative DCF ﬂuorescence was expressed
d TNF-α (right panel) were analyzed in culture medium harvested at the indicated






















































Fig. 5. Negative regulation of the Jak2–Stat5 pathway by PrdxV. To investigate the signaling pathway by which PrdxV negatively regulates IL-6, activation of NF-κB, MAPKs,
and Jak2–Stat5 was analyzed. (A) Raw264.7 cells expressing PrdxVMock or PrdxVWT were stimulated with 1 μg/ml LPS for the indicated times (0, 15, 30, 45, and 60 min).
Levels of activated JNK, ERK1/2, and p38 were then determined by Western blotting using anti-P-JNK, anti-P-c-Jun, anti-P-ERK1/2, and anti-P-p38 antibodies. Activation of
NF-κB was veriﬁed based on IκBα degradation and phosphorylation of NF-κB p65. (B) Raw264.7 cells expressing PrdxVMock and PrdxVWT were stimulated with 1 μg/ml LPS for
the indicated times (0, 3, and 6 h), after which induction of IκBζ was indirectly assessed based on G-CSF mRNA levels. (C) Raw264.7 cells expressing PrdxVMock, PrdxVWT, or
PrdxVC48S were stimulated with 1 μg/ml of LPS for the indicated times (0, 3, 6, and 12 h), after which levels of activated Jak2 and Stat5 were determined using anti-phospho-
Jak2 and anti-phospho-Stat5 antibodies. Total protein levels were determined using antibodies against total (T)-Jak2, T-Stat5, SOCS1, and PrdxV. β-Actin served as a loading
control.
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tion, and total Jak2 and Stat5 levels were also unchanged (Fig. 5C).
SOCS1 plays a key role in the negative regulation of cytokine-
induced Jak–Stat pathways [5,31]. However, our ﬁndings showed
that PrdxV does not act by inﬂuencing SOCS1 expression, as SOCS1
levels did not differ in LPS-treated PrdxVMock, PrdxVWT, and
PrdcVC48S cells (Fig. 5C). Taken together, these results suggest that
PrdxV selectively modulates Jak2–Stat5 signaling related to IL-6
expression.
PrdxV interacts with Jak2 via catalytic Cys48
We next investigated how Cys48 of PrdxV is involved in the
regulation of Jak2–Stat5 signaling, and whether any of the other
Cys residues in PrdxV are involved. To explore the mechanism by
which PrdxV regulates the Jak2–Stat5 pathway, we performed pull
down assays using 293-mTLR4-MD2-CD14 cells, which stably
express all three components (mTLR4, MD2, CD14) needed for
LPS-mediated TLR4 activation. These cells were cotransfected with
WT or a mutant (C48S, C73S, C152S, C48/152S) PrdxV using a
HA-tagged vector along with GFP-tagged Jak2 and Myc-tagged
Stat5b expression constructs. Interestingly, a speciﬁc interaction
between PrdxV and Jak2 was detected in the absence or presence
of LPS stimulation (0.1 μg/ml LPS, Fig. 6), whereas no PrdxV–Stat5
or Jak2–Stat5 interactions were detected under any conditions.
Furthermore, WT PrdxV and the C73S and C152S mutants all
signiﬁcantly bound Jak2, whereas the C48S and C48/152S mutants
did not. Given these ﬁndings, we propose that PrdxV speciﬁcallyand directly interacts with Jak2 via Cys48 to regulate the Jak2-
mediated Stat5 signaling.
Like SOCS1, PrdxV is involved in Jak2-mediated Stat5 regulation
To compare the efﬁciencies of PrdxV and SOCS1 as negative
modulators of Jak2–Stat5 activation, we assessed the effect of
PrdxV, alone or with SOCS1, in LPS-treated 293-mTLR MD2-CD14
cells. Consistent with results in Fig. 5C, WT PrdxV substantially
reduced levels of phospho-Jak2, though not completely (Fig. 7A).
By contrast, SOCS1 clearly reduced activation of Jak2–Stat5 to
baseline levels. In addition, the amount of PrdxV pulled-downed
with Jak2 (anti-GFP agarose) and the amount of Jak2 pulled-
downed with PrdxV (anti-HA agarose) were both lower when
PrdxV and SOCS1 were expressed together than when PrdxV was
expressed alone. This suggests that PrdxV and SOCS1 likely
compete for binding to Jak2, and that PrdxV is one of a number
of negative modulators, including SOC1, exerting effects on the
Jak2–Stat5 pathway via interaction with Jak2.Discussion
In this study, we demonstrated that PrdxV plays an essential
role in regulating LPS-induced IL-6 production via modulation of
the Jak2–Stat5 signaling pathway (Fig. 8). LPS stimulation
increases intracellular ROS levels, which in turn activate various
signaling cascades (e.g., NF-κB, MAPK, and Jak2–Stat5 pathways),
Fig. 6. Interaction between PrdxV and Jak2. To determine whether there was a
direct interaction between PrdxV and Jak2 and/or Stat5, 293-mTLR4-MD2-CD14
cells were cotransfected with Jak2, Stat5b, and PrdxV (WT or a cysteine mutant:
C48S, C73S, C152S, or C48/152S) tagged with GFP, Myc, and HA, respectively. After
incubating the transfectants with 0.1 μg/ml LPS for 3 h, they were lysed and the
lysates were immunoprecipitated, separated by SDS-PAGE (reducing gel), and
immunoblotted using anti-GFP, anti-Myc, and anti-HA antibodies. Expression of









Fig. 7. Efﬁciency of PrdxV as negative modulator of Jak2–Stat5 activation. To assess the e
known negative modulator of Jak2–Stat5 signaling, were compared in 293-mTLR4-MD2
left untreated or stimulated with 0.1 μg/ml LPS for 3 h, they were lysed, and the
immunoblotted using the appropriate antibodies. β-Actin served as a loading contr
immunoprecipitated using HA-agarose beads (upper panel in B) and GFP-agarose beads
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TNF-α and IL-6), but also to up-regulation of PrdxV. However,
unlike the effect of the antioxidant NAC, which inhibits all the
effects of ROS, PrdxV functions as a speciﬁc regulator of Jak2–Stat5
activation. In the proposed mechanism, PrdxV directly interacts
with Jak2 via its catalytic Cys48 residue, which inhibits the
sequential phosphorylation of Jak2 and Stat5 induced by LPS
and, in turn, reduces IL-6 levels. We therefore propose that
PrdxV acts as a negative modulator of Jak2 activation through a
mechanism involving protein–protein interaction, but not perox-
idase activity. That is, PrdxV appears to regulate IL-6 levels by














fﬁciency of PrdxV activity toward Jak2–Stat5, the effects of PrdxV and SOSC1, a well-
-CD14 cells transfected with the indicated tagged proteins. (A) The cells were then
lysates were immunoprecipitated, separated by SDS-PAGE (reducing gel), and
ol. (B) Cells expressing the indicated tagged proteins were lysed, sequentially











Fig. 8. Proposed mechanism by which PrdxV inhibits LPS-induced IL-6 production.
Within macrophages, LPS stimulation generates reactive oxygen species (ROS),
which activate Jak2–Stat5 signaling leading to production of IL-6. At the same time,
LPS-induced ROS generation also stimulates expression of PrdxV, which acts as an
antioxidant. However, the overexpressed PrdxV does not directly reduce LPS-
stimulated ROS levels. Instead, PrdxV interacts with Jak2 via its catalytic Cys48
residue, which inhibits phosphorylation of Jak2 and, in turn, Stat5, thereby
diminishing IL-6 production.
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induced in LPS-treated Raw264.7 cells (Fig. 1C), and activation of
Jak2–Stat5 by LPS is well known to be a cytosolic event.
It was recently suggested that PrdxII is a negative regulator of LPS-
induced inﬂammatory signaling via ROS synthesis [28]. Consistent
with that idea, macrophages from PrdxII-deﬁcient mice produce
greater amounts of TNF-α and IL-6 following LPS stimulation as a
result of hyperactivation of the NF-κB and JNK, ERK and p38 MAPK
pathways. Moreover, the effects correlated with elevated intracellular
levels of H2O2 in the PrdxII-deﬁcient macrophages. It has also been
reported that PrdxV modulates redox-sensitive neuroinﬂammatory
cytokine production [23]. In the present study, however, we observed
a speciﬁc reduction in LPS-induced IL-6 production in PrdxVWT cells,
with no effect on other cytokines (Fig. 2 and Supplementary Fig. S2).
In addition, although the catalytic cysteine of PrdxV, Cys48, is clearly
involved in the regulation of IL-6 production via the Jak2–Stat5
pathway (Figs. 4 and 5C), the ability of PrdxV to affect LPS-induced
ROS levels did not differ in PrdxVMock, PrdxVWT, and PrdxVC48S cells
(Fig. 4B). By contrast, removing ROS using the well-known chemical
antioxidant NAC or the well-known peroxidase enzyme PrdxII and
catalase nonspeciﬁcally inhibited LPS-stimulated proinﬂammatory
cytokine signals (IL-6 or TNF-α) as well as LPS-induced PrdxV induc-
tion (Fig. 3 and Supplementary Fig. S3A and S3C–E). Likewise,
LPS-induced Jak2–Stat5 activation (phosphorylation) was reduced by
NAC (Supplementary Fig. S3B). In other words, PrdxV expressed in
response to LPS stimulation does not act as an antioxidant that inhibits
all proinﬂammatory cytokine signaling; instead, it functions speciﬁ-
cally to regulate IL-6.
It is noteworthy that the serial phosphorylation of Jak2 and
Stat5 was affected by the up-regulation of PrdxV. In both stable
and transient expression systems, overexpression of PrdxV inhib-
ited the sequential activation of Jak2 and Stat5, leading to IL-6
production (Fig. 2 and Figs. 5C and 7A). This suggests that PrdxV is
directly involved in the activation of the Jak2–Stat5 pathway. Our
ﬁndings indicate that exogenously expressed PrdxV interacts with
Jak2 in LPS-treated 293-mTLR4-MD2-CD14 cells, and that their
interaction is lost when Cys48 of PrdxV is substituted with Ser
(Fig. 6). We therefore hypothesize that PrdxV acts to inhibit IL-6
through Jak2-dependent Stat5 inhibition mediated by protein–
protein interaction.
Canonical and noncanonical activation of Jak2 is regulated by
various mechanisms and molecules, including phosphorylation,
nitration, pseudokinase domains, adaptor proteins, and reactive
oxygen and nitrogen species (ROS/RNS) [32]. Among these, reg-
ulation of Jak activity by ROS/RNS remains controversial, in part
because activation of Jak2 by ROS is often indirect [33,34]. For
example, indirect activation of Jak2 may result from oxidative
inhibition of the active site Cys in protein tyrosine phosphatases,
which increases phosphotyrosine levels in Jak2 [35–37]. GPCR-
mediated Jak2 activation and angiotensin II-induced Jak2 activa-
tion also involves subsequent activation of NADPH oxidase [38,39].
In vivo, Jak2 is activated in cardiac myocytes by acute oxidative
stress, although the precise mechanism is unknown [40,41].
Inactivation of Jak2 by oxidants has been mainly studied using a
biochemical approach. For example, the thiol redox status of Jak2
and Jak3 was recently shown to affect autokinase activity [42]. In
particular, the four Cys residues in the catalytic domain (Cys866,
Cys917, Cys1094, and Cys1105) are closely involved in maintaining
Jak2′s catalytic activity [43]. In addition, oxidative stress was
shown to inhibit the secretion of ciliary neurotrophic factor
(CNTF), which was mediated by Jak2, in H2O2-treated nerve cells
[44], and parthenolide-induced oxidative stress inhibits Jak1
activity [45]. In the present study, we showed that the peroxidase
activity of PrdxV does not meaningfully affect LPS-induced ROS
production in macrophages (Fig. 5B), though it is a critical for
macrophage activation [46]. Instead, we found that Cys48 of PrdxVis involved in the PrdxV–Jak2 interaction (Fig. 6). The Jak2 domain
or residues involved in the interaction remain to be determined.
It has been reported that SOCS1 selectively inhibits LPS-
induced IL-6 production by regulating the Jak2–Stat5 signaling
pathway [5]. The regulation of Jak2–Stat5 activation by PrdxV was
not as efﬁcient as that by SOCS1 in LPS-treated 293-mTLR4-MD2-
CD14 cells (Fig. 7B). Nonetheless, our results clearly indicate that
PrdxV speciﬁcally and negatively regulates the Jak2–Stat5 pathway
to IL-6 production following LPS stimulation. SOCS1 protein
contains a kinase inhibitory region (KIR), which is thought to
function as a pseudosubstrate; a central Src Homology 2 (SH2)
domain; and a conserved C-terminal region, which is referred to as
a SOCS box [47]. SOCS1 directly regulates Jak2 activity by binding
to the activation loop of the catalytic domain through both its KIR
and its SH2 domains. PrdxV does not contain a SH2 domain.
Therefore, the structural basis for its interaction with Jak2 likely
differs from that of SOCS1 and remains to be characterized.
In summary, we have demonstrated that cytosolic PrdxV plays a
key role in negatively regulating LPS-induced IL-6 production through
an inhibitory effect on Jak2–Stat5 signaling. PrdxV appears to act by
binding to Jak2 via its catalytic Cys48 residue, though it does not
involve its peroxidase activity. Although the mechanism by which
PrdxV interacts with Jak2 likely differs from SOCS1, our ﬁndings
suggest that PrdxV is involved in LPS-mediated innate immunity.Acknowledgments
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